Source: Health Products Regulatory Authority (IE) Revision Year: 2021 Publisher: Reckitt Benckiser Ireland Ltd, 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Pharmacotherapeutic group: Respiratory system, Cough and cold preparations, Expectorants
ATC Code: R05CA03
Guaifenesin is an expectorant which increases the volume of mucous that can be expelled or cleared by mucocilliary action due to reduction in the adhesiveness and viscosity of tenacious sputum.
The active ingredients are not known to cause sedation.
Guaifenesin is readily absorbed from the gastrointestinal tract after oral administration and rapidly metabolised by oxidation to β-(2-methoxyphenoxy)-lactic acid. Approximately 40% of a dose is excreted as this metabolite in the urine within three hours. The half-life in plasma is approximately one hour.
No preclinical findings of relevance to the prescriber have been reported.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
